Basic Information
| LncRNA/CircRNA Name | HULC |
| Synonyms | NA |
| Region | GRCh38_6:8435568-9294133 |
| Ensemble | ENSG00000251164 |
| Refseq | NR_004855 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | YK-4-279 | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Ewing sarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | ES cell line LAP-35, ES cell line TC-71 and SK-N-MC |
| Expression Pattern | up-regulated |
| Function Description | the lncRNA HULC (Highly Upregulated in Liver Cancer) as a prominent target of YK-4-279 activity in ES cells. High levels of HULC correlate with ES aggressiveness, whereas HULC depletion reduces ES cell growth. Mechanistically, we find that HULC promotes the expression of TWIST1 oncogene by sponging miR-186. Downregulation of HULC upon treatment with YK-4-279 reduces the expression of TWIST1 by unleashing miR-186 and favoring its binding to TWIST1 transcripts. Notably, high levels of miR-186 and low levels of TWIST1 correlate with better prognosis in ES patients. |
| Pubmed ID | 31639426 |
| Year | 2019 |
| Title | Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULC |
External Links
| Links for HULC | GenBank HGNC NONCODE |
| Links for Ewing sarcoma | OMIM COSMIC |